Clinical Precision Imaging

Precision Neuroimaging of Brain Disorders


The field of Magnetic Resonance Imaging (MRI) continues to advance, expanding the possibilities to study how brain disorders affect the brain´s structure, function, and metabolism. We exploit the enormous biomedical potential of MRI to establish MR-based Precision Medicine as a powerful interface between diagnostic radiology and the clinical neurosciences. 

Our goal is to identify clinically relevant MR-based markers that provide relevant information about the individual risk or prognosis with respect to the course of disease or to response to treatment. This will boost the role of MRI as a clinical tool that can help neurologists, neurosurgeons, and psychiatrists to tailor their therapy to the individual needs of their patients.

Embedded in a large University Hospital, researchers at DRCMR have long-standing collaborations with numerous clinical research groups in the Capital Region of Denmark. Our clinical neuroimaging research covers a wide range of psychiatric and neurologic disorders as well as the entire life span. The Clinical Precision Imaging area is closely intertwined with and capitalizes on the specific expertise and outcomes of the MR Physics & Analysis, Transcranial Brain Stimulation, Cognitive & Computational Neuroscience and Life Span Imaging research areas. 


We develop and validate novel MR-based technologies which can reliably capture risk, resilience or disease-related structural, functional, metabolic changes in the brain. In parallel, we develop and advance neuroimaging data-analysis tools. MR-based imaging technologies and analytical tools are optimized to reliably identify clinically relevant MR-based “read-outs”. It is our aim to further optimize the value of MR-based precision medicine by integrating longitudinal electronic health data (E-health) and genomic and biochemical data (“Omics”). Another line of our research is concerned with exploiting MRI-based techniques to individualize the use of non-invasive transcranial brain stimulation (NTBS) in order to maximize therapeutic efficiency.


Our research will yield novel MR protocols that pick-up disease-causing (pathogenesis) or disability-causing (pathophysiology) processes at high sensitivity and specificity. It is our aim to establish predictive MR-based neuroimaging markers (“read outs”) to assist clinical decision making and personalized medicine. Another aim is to identify pre-symptomatic MRI-based neuroimaging markers of disease formation in cohorts bearing increased risk or resilience (reduced risk) for a neurologic (e.g. Parkinson´s disease) or psychiatric (e.g. schizophrenia) disorder and in large population cohorts. Finally, we wish to establish novel MRI-based neuroimaging markers for the presence or magnitude of common disabling symptoms that can be used to test and monitor the efficiency of symptomatic treatments at the individual level.


Axial Magnetic Resonance Image (MRI) showing characteristic disease-related white matter alterations in a patient with multiple sclerosis

Selected Publications

Miskowiak, K. W., Macoveanu, J., Jørgensen, M. B., Støttrup, M. M., Ott, C. V., Jensen, H. M., Jørgensen, A., Harmer, J., Paulson, O. B., Kessing, L. V. & Siebner, H. R. Neural Response After a Single ECT Session During Retrieval of Emotional Self-Referent Words in Depression: A Randomized, Sham-Controlled fMRI Study. International Journal of Neuropsychopharmacology. 21, 3, p. 226-235, 2017.

Fisher, P. M., Larsen, C. B., Beliveau, V., Henningsson, S., Pinborg, A., Holst, K. K., Jensen, P. S., Svarer, C., Siebner, H. R., Knudsen, G. M. & Frokjaer, V. G. Pharmacologically Induced Sex-Hormone Fluctuation Effects on Resting-State Functional Connectivity in a Risk Model for Depression: A Randomised Trial. Neuropsychopharmacology. 42, 2, p. 446-453, 2017.

Dogonowski, A.M., Blinkenberg, M., Paulsonm O.B., Sellebjergm F., Sørensen, P.S., Siebner, H.R., Madsen, K.H. Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis. J Neurol Neurosurg Psychiatry 87, 8, p. 912-914, 2016. 

Gaist, D., Garde, E., Blaabjerg, M., Nielsen, H.H., Krøigård, T., Østergaard, K., Møller, H.S., Hjelmborg, J., Madsen, C.G., Iversen, P., Kyvik, K.O., Siebner, H.R., Ashina, M. Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. Brain. 139, 7, 2015-2023, 2016.

Gelskov, S.V., Madsen, K.H., Ramsøy, T.Z., Siebner, H.R. Aberrant neural signatures of decision-making: Pathological gamblers display cortico-striatal hypersensitivity to extreme gambles. Neuroimage. 128, 342-352, 2016.

Herz, D.M., B.N. Haagensen, M.S. Christensen, et al. Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. Brain 138, p. 1658-1666, 2015.

Løkkegaard, A., Herz, D.M., Haagensen, B.N., Lorentzen, A.K., Eickhoff, S.B., Siebner, H.R. Altered sensorimotor activation patterns in idiopathic dystonia-an activation likelihood estimation meta-analysis of functional brain imaging studies. Hum Brain Mapp. 37, 2, p. 547-557, 2016.

Macoveanu, J., Miskowiak, K., Kessing, L.V., Vinberg, M., Siebner, H.R. Healthy co-twins of patients with affective disorders show reduced risk-related activation of the insula during a monetary gambling task. J Psychiatry Neurosci. 41, 1, p. 38-47, 2016.


Research Members

Kasper Winther Andersen

Research Area Coordinator

Kristoffer Hougaard Madsen

Tim Dyrby

David Meder

Show all associated staff